Global Varicella Attenuated Live Vaccine Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Varicella Attenuated Live Vaccine market size is predicted to grow from US$ 2821 million in 2025 to US$ 3665 million in 2031; it is expected to grow at a CAGR of 4.5% from 2025 to 2031.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
LP Information, Inc. (LPI) ' newest research report, the “Varicella Attenuated Live Vaccine Industry Forecast” looks at past sales and reviews total world Varicella Attenuated Live Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Varicella Attenuated Live Vaccine sales for 2025 through 2031. With Varicella Attenuated Live Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Varicella Attenuated Live Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Varicella Attenuated Live Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Varicella Attenuated Live Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Varicella Attenuated Live Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Varicella Attenuated Live Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Varicella Attenuated Live Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Varicella Attenuated Live Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Varicella Attenuated Live Vaccine market?
What factors are driving Varicella Attenuated Live Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Varicella Attenuated Live Vaccine market opportunities vary by end market size?
How does Varicella Attenuated Live Vaccine break out by Type, by Application?
The global Varicella Attenuated Live Vaccine market size is predicted to grow from US$ 2821 million in 2025 to US$ 3665 million in 2031; it is expected to grow at a CAGR of 4.5% from 2025 to 2031.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
LP Information, Inc. (LPI) ' newest research report, the “Varicella Attenuated Live Vaccine Industry Forecast” looks at past sales and reviews total world Varicella Attenuated Live Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Varicella Attenuated Live Vaccine sales for 2025 through 2031. With Varicella Attenuated Live Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Varicella Attenuated Live Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Varicella Attenuated Live Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Varicella Attenuated Live Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Varicella Attenuated Live Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Varicella Attenuated Live Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Varicella Attenuated Live Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Varicella Attenuated Live Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Monovalent Vaccine
- Combination Vaccine
- Kids Injection
- Adults Injection
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck
- BCHT
- Shanghai Institute
- GSK
- Keygen
- Green Cross
- Biken
- Shanghai Rongsheng Biotech
- Changchun Changsheng Life Sciences Limited
What is the 10-year outlook for the global Varicella Attenuated Live Vaccine market?
What factors are driving Varicella Attenuated Live Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Varicella Attenuated Live Vaccine market opportunities vary by end market size?
How does Varicella Attenuated Live Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Varicella Attenuated Live Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Varicella Attenuated Live Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Varicella Attenuated Live Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Varicella Attenuated Live Vaccine Segment by Type
2.2.1 Monovalent Vaccine
2.2.2 Combination Vaccine
2.3 Varicella Attenuated Live Vaccine Sales by Type
2.3.1 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
2.3.2 Global Varicella Attenuated Live Vaccine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Varicella Attenuated Live Vaccine Sale Price by Type (2020-2025)
2.4 Varicella Attenuated Live Vaccine Segment by Application
2.4.1 Kids Injection
2.4.2 Adults Injection
2.5 Varicella Attenuated Live Vaccine Sales by Application
2.5.1 Global Varicella Attenuated Live Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Varicella Attenuated Live Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Varicella Attenuated Live Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Varicella Attenuated Live Vaccine Breakdown Data by Company
3.1.1 Global Varicella Attenuated Live Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Varicella Attenuated Live Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
3.2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Varicella Attenuated Live Vaccine Sale Price by Company
3.4 Key Manufacturers Varicella Attenuated Live Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Varicella Attenuated Live Vaccine Product Location Distribution
3.4.2 Players Varicella Attenuated Live Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VARICELLA ATTENUATED LIVE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Varicella Attenuated Live Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Varicella Attenuated Live Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Varicella Attenuated Live Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Varicella Attenuated Live Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Varicella Attenuated Live Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Varicella Attenuated Live Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Varicella Attenuated Live Vaccine Sales Growth
4.4 APAC Varicella Attenuated Live Vaccine Sales Growth
4.5 Europe Varicella Attenuated Live Vaccine Sales Growth
4.6 Middle East & Africa Varicella Attenuated Live Vaccine Sales Growth
5 AMERICAS
5.1 Americas Varicella Attenuated Live Vaccine Sales by Country
5.1.1 Americas Varicella Attenuated Live Vaccine Sales by Country (2020-2025)
5.1.2 Americas Varicella Attenuated Live Vaccine Revenue by Country (2020-2025)
5.2 Americas Varicella Attenuated Live Vaccine Sales by Type (2020-2025)
5.3 Americas Varicella Attenuated Live Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Varicella Attenuated Live Vaccine Sales by Region
6.1.1 APAC Varicella Attenuated Live Vaccine Sales by Region (2020-2025)
6.1.2 APAC Varicella Attenuated Live Vaccine Revenue by Region (2020-2025)
6.2 APAC Varicella Attenuated Live Vaccine Sales by Type (2020-2025)
6.3 APAC Varicella Attenuated Live Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Varicella Attenuated Live Vaccine by Country
7.1.1 Europe Varicella Attenuated Live Vaccine Sales by Country (2020-2025)
7.1.2 Europe Varicella Attenuated Live Vaccine Revenue by Country (2020-2025)
7.2 Europe Varicella Attenuated Live Vaccine Sales by Type (2020-2025)
7.3 Europe Varicella Attenuated Live Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Varicella Attenuated Live Vaccine by Country
8.1.1 Middle East & Africa Varicella Attenuated Live Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Varicella Attenuated Live Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Varicella Attenuated Live Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Varicella Attenuated Live Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Varicella Attenuated Live Vaccine
10.3 Manufacturing Process Analysis of Varicella Attenuated Live Vaccine
10.4 Industry Chain Structure of Varicella Attenuated Live Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Varicella Attenuated Live Vaccine Distributors
11.3 Varicella Attenuated Live Vaccine Customer
12 WORLD FORECAST REVIEW FOR VARICELLA ATTENUATED LIVE VACCINE BY GEOGRAPHIC REGION
12.1 Global Varicella Attenuated Live Vaccine Market Size Forecast by Region
12.1.1 Global Varicella Attenuated Live Vaccine Forecast by Region (2026-2031)
12.1.2 Global Varicella Attenuated Live Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Varicella Attenuated Live Vaccine Forecast by Type (2026-2031)
12.7 Global Varicella Attenuated Live Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 BCHT
13.2.1 BCHT Company Information
13.2.2 BCHT Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 BCHT Main Business Overview
13.2.5 BCHT Latest Developments
13.3 Shanghai Institute
13.3.1 Shanghai Institute Company Information
13.3.2 Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Shanghai Institute Main Business Overview
13.3.5 Shanghai Institute Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 Keygen
13.5.1 Keygen Company Information
13.5.2 Keygen Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Keygen Main Business Overview
13.5.5 Keygen Latest Developments
13.6 Green Cross
13.6.1 Green Cross Company Information
13.6.2 Green Cross Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Green Cross Main Business Overview
13.6.5 Green Cross Latest Developments
13.7 Biken
13.7.1 Biken Company Information
13.7.2 Biken Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.7.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Biken Main Business Overview
13.7.5 Biken Latest Developments
13.8 Shanghai Rongsheng Biotech
13.8.1 Shanghai Rongsheng Biotech Company Information
13.8.2 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Shanghai Rongsheng Biotech Main Business Overview
13.8.5 Shanghai Rongsheng Biotech Latest Developments
13.9 Changchun Changsheng Life Sciences Limited
13.9.1 Changchun Changsheng Life Sciences Limited Company Information
13.9.2 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Changchun Changsheng Life Sciences Limited Main Business Overview
13.9.5 Changchun Changsheng Life Sciences Limited Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Varicella Attenuated Live Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Varicella Attenuated Live Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Varicella Attenuated Live Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Varicella Attenuated Live Vaccine Segment by Type
2.2.1 Monovalent Vaccine
2.2.2 Combination Vaccine
2.3 Varicella Attenuated Live Vaccine Sales by Type
2.3.1 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
2.3.2 Global Varicella Attenuated Live Vaccine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Varicella Attenuated Live Vaccine Sale Price by Type (2020-2025)
2.4 Varicella Attenuated Live Vaccine Segment by Application
2.4.1 Kids Injection
2.4.2 Adults Injection
2.5 Varicella Attenuated Live Vaccine Sales by Application
2.5.1 Global Varicella Attenuated Live Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Varicella Attenuated Live Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Varicella Attenuated Live Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Varicella Attenuated Live Vaccine Breakdown Data by Company
3.1.1 Global Varicella Attenuated Live Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Varicella Attenuated Live Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
3.2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Varicella Attenuated Live Vaccine Sale Price by Company
3.4 Key Manufacturers Varicella Attenuated Live Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Varicella Attenuated Live Vaccine Product Location Distribution
3.4.2 Players Varicella Attenuated Live Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VARICELLA ATTENUATED LIVE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Varicella Attenuated Live Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Varicella Attenuated Live Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Varicella Attenuated Live Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Varicella Attenuated Live Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Varicella Attenuated Live Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Varicella Attenuated Live Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Varicella Attenuated Live Vaccine Sales Growth
4.4 APAC Varicella Attenuated Live Vaccine Sales Growth
4.5 Europe Varicella Attenuated Live Vaccine Sales Growth
4.6 Middle East & Africa Varicella Attenuated Live Vaccine Sales Growth
5 AMERICAS
5.1 Americas Varicella Attenuated Live Vaccine Sales by Country
5.1.1 Americas Varicella Attenuated Live Vaccine Sales by Country (2020-2025)
5.1.2 Americas Varicella Attenuated Live Vaccine Revenue by Country (2020-2025)
5.2 Americas Varicella Attenuated Live Vaccine Sales by Type (2020-2025)
5.3 Americas Varicella Attenuated Live Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Varicella Attenuated Live Vaccine Sales by Region
6.1.1 APAC Varicella Attenuated Live Vaccine Sales by Region (2020-2025)
6.1.2 APAC Varicella Attenuated Live Vaccine Revenue by Region (2020-2025)
6.2 APAC Varicella Attenuated Live Vaccine Sales by Type (2020-2025)
6.3 APAC Varicella Attenuated Live Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Varicella Attenuated Live Vaccine by Country
7.1.1 Europe Varicella Attenuated Live Vaccine Sales by Country (2020-2025)
7.1.2 Europe Varicella Attenuated Live Vaccine Revenue by Country (2020-2025)
7.2 Europe Varicella Attenuated Live Vaccine Sales by Type (2020-2025)
7.3 Europe Varicella Attenuated Live Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Varicella Attenuated Live Vaccine by Country
8.1.1 Middle East & Africa Varicella Attenuated Live Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Varicella Attenuated Live Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Varicella Attenuated Live Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Varicella Attenuated Live Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Varicella Attenuated Live Vaccine
10.3 Manufacturing Process Analysis of Varicella Attenuated Live Vaccine
10.4 Industry Chain Structure of Varicella Attenuated Live Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Varicella Attenuated Live Vaccine Distributors
11.3 Varicella Attenuated Live Vaccine Customer
12 WORLD FORECAST REVIEW FOR VARICELLA ATTENUATED LIVE VACCINE BY GEOGRAPHIC REGION
12.1 Global Varicella Attenuated Live Vaccine Market Size Forecast by Region
12.1.1 Global Varicella Attenuated Live Vaccine Forecast by Region (2026-2031)
12.1.2 Global Varicella Attenuated Live Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Varicella Attenuated Live Vaccine Forecast by Type (2026-2031)
12.7 Global Varicella Attenuated Live Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 BCHT
13.2.1 BCHT Company Information
13.2.2 BCHT Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 BCHT Main Business Overview
13.2.5 BCHT Latest Developments
13.3 Shanghai Institute
13.3.1 Shanghai Institute Company Information
13.3.2 Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Shanghai Institute Main Business Overview
13.3.5 Shanghai Institute Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 Keygen
13.5.1 Keygen Company Information
13.5.2 Keygen Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Keygen Main Business Overview
13.5.5 Keygen Latest Developments
13.6 Green Cross
13.6.1 Green Cross Company Information
13.6.2 Green Cross Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Green Cross Main Business Overview
13.6.5 Green Cross Latest Developments
13.7 Biken
13.7.1 Biken Company Information
13.7.2 Biken Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.7.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Biken Main Business Overview
13.7.5 Biken Latest Developments
13.8 Shanghai Rongsheng Biotech
13.8.1 Shanghai Rongsheng Biotech Company Information
13.8.2 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Shanghai Rongsheng Biotech Main Business Overview
13.8.5 Shanghai Rongsheng Biotech Latest Developments
13.9 Changchun Changsheng Life Sciences Limited
13.9.1 Changchun Changsheng Life Sciences Limited Company Information
13.9.2 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolios and Specifications
13.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Changchun Changsheng Life Sciences Limited Main Business Overview
13.9.5 Changchun Changsheng Life Sciences Limited Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Varicella Attenuated Live Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Varicella Attenuated Live Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Monovalent Vaccine
Table 4. Major Players of Combination Vaccine
Table 5. Global Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 6. Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 7. Global Varicella Attenuated Live Vaccine Revenue by Type (2020-2025) & ($ million)
Table 8. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2020-2025)
Table 9. Global Varicella Attenuated Live Vaccine Sale Price by Type (2020-2025) & (USD/Dose)
Table 10. Global Varicella Attenuated Live Vaccine Sale by Application (2020-2025) & (K Doses)
Table 11. Global Varicella Attenuated Live Vaccine Sale Market Share by Application (2020-2025)
Table 12. Global Varicella Attenuated Live Vaccine Revenue by Application (2020-2025) & ($ million)
Table 13. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2020-2025)
Table 14. Global Varicella Attenuated Live Vaccine Sale Price by Application (2020-2025) & (USD/Dose)
Table 15. Global Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 16. Global Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 17. Global Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 19. Global Varicella Attenuated Live Vaccine Sale Price by Company (2020-2025) & (USD/Dose)
Table 20. Key Manufacturers Varicella Attenuated Live Vaccine Producing Area Distribution and Sales Area
Table 21. Players Varicella Attenuated Live Vaccine Products Offered
Table 22. Varicella Attenuated Live Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Varicella Attenuated Live Vaccine Sales by Geographic Region (2020-2025) & (K Doses)
Table 26. Global Varicella Attenuated Live Vaccine Sales Market Share Geographic Region (2020-2025)
Table 27. Global Varicella Attenuated Live Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Varicella Attenuated Live Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Varicella Attenuated Live Vaccine Sales by Country/Region (2020-2025) & (K Doses)
Table 30. Global Varicella Attenuated Live Vaccine Sales Market Share by Country/Region (2020-2025)
Table 31. Global Varicella Attenuated Live Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Varicella Attenuated Live Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Varicella Attenuated Live Vaccine Sales by Country (2020-2025) & (K Doses)
Table 34. Americas Varicella Attenuated Live Vaccine Sales Market Share by Country (2020-2025)
Table 35. Americas Varicella Attenuated Live Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 37. Americas Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 38. APAC Varicella Attenuated Live Vaccine Sales by Region (2020-2025) & (K Doses)
Table 39. APAC Varicella Attenuated Live Vaccine Sales Market Share by Region (2020-2025)
Table 40. APAC Varicella Attenuated Live Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 42. APAC Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 43. Europe Varicella Attenuated Live Vaccine Sales by Country (2020-2025) & (K Doses)
Table 44. Europe Varicella Attenuated Live Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 46. Europe Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 47. Middle East & Africa Varicella Attenuated Live Vaccine Sales by Country (2020-2025) & (K Doses)
Table 48. Middle East & Africa Varicella Attenuated Live Vaccine Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 50. Middle East & Africa Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 51. Key Market Drivers & Growth Opportunities of Varicella Attenuated Live Vaccine
Table 52. Key Market Challenges & Risks of Varicella Attenuated Live Vaccine
Table 53. Key Industry Trends of Varicella Attenuated Live Vaccine
Table 54. Varicella Attenuated Live Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Varicella Attenuated Live Vaccine Distributors List
Table 57. Varicella Attenuated Live Vaccine Customer List
Table 58. Global Varicella Attenuated Live Vaccine Sales Forecast by Region (2026-2031) & (K Doses)
Table 59. Global Varicella Attenuated Live Vaccine Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Varicella Attenuated Live Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 61. Americas Varicella Attenuated Live Vaccine Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Varicella Attenuated Live Vaccine Sales Forecast by Region (2026-2031) & (K Doses)
Table 63. APAC Varicella Attenuated Live Vaccine Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Varicella Attenuated Live Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 65. Europe Varicella Attenuated Live Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Varicella Attenuated Live Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 67. Middle East & Africa Varicella Attenuated Live Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Varicella Attenuated Live Vaccine Sales Forecast by Type (2026-2031) & (K Doses)
Table 69. Global Varicella Attenuated Live Vaccine Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Varicella Attenuated Live Vaccine Sales Forecast by Application (2026-2031) & (K Doses)
Table 71. Global Varicella Attenuated Live Vaccine Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Merck Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Merck Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 74. Merck Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 75. Merck Main Business
Table 76. Merck Latest Developments
Table 77. BCHT Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. BCHT Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 79. BCHT Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 80. BCHT Main Business
Table 81. BCHT Latest Developments
Table 82. Shanghai Institute Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 84. Shanghai Institute Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 85. Shanghai Institute Main Business
Table 86. Shanghai Institute Latest Developments
Table 87. GSK Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. GSK Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 89. GSK Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 90. GSK Main Business
Table 91. GSK Latest Developments
Table 92. Keygen Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Keygen Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 94. Keygen Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 95. Keygen Main Business
Table 96. Keygen Latest Developments
Table 97. Green Cross Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. Green Cross Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 99. Green Cross Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 100. Green Cross Main Business
Table 101. Green Cross Latest Developments
Table 102. Biken Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Biken Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 104. Biken Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 105. Biken Main Business
Table 106. Biken Latest Developments
Table 107. Shanghai Rongsheng Biotech Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 109. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 110. Shanghai Rongsheng Biotech Main Business
Table 111. Shanghai Rongsheng Biotech Latest Developments
Table 112. Changchun Changsheng Life Sciences Limited Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 114. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 115. Changchun Changsheng Life Sciences Limited Main Business
Table 116. Changchun Changsheng Life Sciences Limited Latest Developments
Table 1. Varicella Attenuated Live Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Varicella Attenuated Live Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Monovalent Vaccine
Table 4. Major Players of Combination Vaccine
Table 5. Global Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 6. Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Table 7. Global Varicella Attenuated Live Vaccine Revenue by Type (2020-2025) & ($ million)
Table 8. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2020-2025)
Table 9. Global Varicella Attenuated Live Vaccine Sale Price by Type (2020-2025) & (USD/Dose)
Table 10. Global Varicella Attenuated Live Vaccine Sale by Application (2020-2025) & (K Doses)
Table 11. Global Varicella Attenuated Live Vaccine Sale Market Share by Application (2020-2025)
Table 12. Global Varicella Attenuated Live Vaccine Revenue by Application (2020-2025) & ($ million)
Table 13. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2020-2025)
Table 14. Global Varicella Attenuated Live Vaccine Sale Price by Application (2020-2025) & (USD/Dose)
Table 15. Global Varicella Attenuated Live Vaccine Sales by Company (2020-2025) & (K Doses)
Table 16. Global Varicella Attenuated Live Vaccine Sales Market Share by Company (2020-2025)
Table 17. Global Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
Table 19. Global Varicella Attenuated Live Vaccine Sale Price by Company (2020-2025) & (USD/Dose)
Table 20. Key Manufacturers Varicella Attenuated Live Vaccine Producing Area Distribution and Sales Area
Table 21. Players Varicella Attenuated Live Vaccine Products Offered
Table 22. Varicella Attenuated Live Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Varicella Attenuated Live Vaccine Sales by Geographic Region (2020-2025) & (K Doses)
Table 26. Global Varicella Attenuated Live Vaccine Sales Market Share Geographic Region (2020-2025)
Table 27. Global Varicella Attenuated Live Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Varicella Attenuated Live Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Varicella Attenuated Live Vaccine Sales by Country/Region (2020-2025) & (K Doses)
Table 30. Global Varicella Attenuated Live Vaccine Sales Market Share by Country/Region (2020-2025)
Table 31. Global Varicella Attenuated Live Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Varicella Attenuated Live Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Varicella Attenuated Live Vaccine Sales by Country (2020-2025) & (K Doses)
Table 34. Americas Varicella Attenuated Live Vaccine Sales Market Share by Country (2020-2025)
Table 35. Americas Varicella Attenuated Live Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 37. Americas Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 38. APAC Varicella Attenuated Live Vaccine Sales by Region (2020-2025) & (K Doses)
Table 39. APAC Varicella Attenuated Live Vaccine Sales Market Share by Region (2020-2025)
Table 40. APAC Varicella Attenuated Live Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 42. APAC Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 43. Europe Varicella Attenuated Live Vaccine Sales by Country (2020-2025) & (K Doses)
Table 44. Europe Varicella Attenuated Live Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 46. Europe Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 47. Middle East & Africa Varicella Attenuated Live Vaccine Sales by Country (2020-2025) & (K Doses)
Table 48. Middle East & Africa Varicella Attenuated Live Vaccine Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Varicella Attenuated Live Vaccine Sales by Type (2020-2025) & (K Doses)
Table 50. Middle East & Africa Varicella Attenuated Live Vaccine Sales by Application (2020-2025) & (K Doses)
Table 51. Key Market Drivers & Growth Opportunities of Varicella Attenuated Live Vaccine
Table 52. Key Market Challenges & Risks of Varicella Attenuated Live Vaccine
Table 53. Key Industry Trends of Varicella Attenuated Live Vaccine
Table 54. Varicella Attenuated Live Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Varicella Attenuated Live Vaccine Distributors List
Table 57. Varicella Attenuated Live Vaccine Customer List
Table 58. Global Varicella Attenuated Live Vaccine Sales Forecast by Region (2026-2031) & (K Doses)
Table 59. Global Varicella Attenuated Live Vaccine Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Varicella Attenuated Live Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 61. Americas Varicella Attenuated Live Vaccine Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Varicella Attenuated Live Vaccine Sales Forecast by Region (2026-2031) & (K Doses)
Table 63. APAC Varicella Attenuated Live Vaccine Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Varicella Attenuated Live Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 65. Europe Varicella Attenuated Live Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Varicella Attenuated Live Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 67. Middle East & Africa Varicella Attenuated Live Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Varicella Attenuated Live Vaccine Sales Forecast by Type (2026-2031) & (K Doses)
Table 69. Global Varicella Attenuated Live Vaccine Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Varicella Attenuated Live Vaccine Sales Forecast by Application (2026-2031) & (K Doses)
Table 71. Global Varicella Attenuated Live Vaccine Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Merck Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Merck Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 74. Merck Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 75. Merck Main Business
Table 76. Merck Latest Developments
Table 77. BCHT Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. BCHT Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 79. BCHT Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 80. BCHT Main Business
Table 81. BCHT Latest Developments
Table 82. Shanghai Institute Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 84. Shanghai Institute Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 85. Shanghai Institute Main Business
Table 86. Shanghai Institute Latest Developments
Table 87. GSK Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. GSK Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 89. GSK Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 90. GSK Main Business
Table 91. GSK Latest Developments
Table 92. Keygen Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Keygen Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 94. Keygen Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 95. Keygen Main Business
Table 96. Keygen Latest Developments
Table 97. Green Cross Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. Green Cross Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 99. Green Cross Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 100. Green Cross Main Business
Table 101. Green Cross Latest Developments
Table 102. Biken Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Biken Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 104. Biken Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 105. Biken Main Business
Table 106. Biken Latest Developments
Table 107. Shanghai Rongsheng Biotech Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 109. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 110. Shanghai Rongsheng Biotech Main Business
Table 111. Shanghai Rongsheng Biotech Latest Developments
Table 112. Changchun Changsheng Life Sciences Limited Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolios and Specifications
Table 114. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 115. Changchun Changsheng Life Sciences Limited Main Business
Table 116. Changchun Changsheng Life Sciences Limited Latest Developments
LIST OF FIGURES
Figure 1. Picture of Varicella Attenuated Live Vaccine
Figure 2. Varicella Attenuated Live Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Varicella Attenuated Live Vaccine Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Varicella Attenuated Live Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Varicella Attenuated Live Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Varicella Attenuated Live Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Varicella Attenuated Live Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Monovalent Vaccine
Figure 12. Product Picture of Combination Vaccine
Figure 13. Global Varicella Attenuated Live Vaccine Sales Market Share by Type in 2025
Figure 14. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2020-2025)
Figure 15. Varicella Attenuated Live Vaccine Consumed in Kids Injection
Figure 16. Global Varicella Attenuated Live Vaccine Market: Kids Injection (2020-2025) & (K Doses)
Figure 17. Varicella Attenuated Live Vaccine Consumed in Adults Injection
Figure 18. Global Varicella Attenuated Live Vaccine Market: Adults Injection (2020-2025) & (K Doses)
Figure 19. Global Varicella Attenuated Live Vaccine Sale Market Share by Application (2024)
Figure 20. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application in 2025
Figure 21. Varicella Attenuated Live Vaccine Sales by Company in 2025 (K Doses)
Figure 22. Global Varicella Attenuated Live Vaccine Sales Market Share by Company in 2025
Figure 23. Varicella Attenuated Live Vaccine Revenue by Company in 2025 ($ millions)
Figure 24. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company in 2025
Figure 25. Global Varicella Attenuated Live Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 26. Global Varicella Attenuated Live Vaccine Revenue Market Share by Geographic Region in 2025
Figure 27. Americas Varicella Attenuated Live Vaccine Sales 2020-2025 (K Doses)
Figure 28. Americas Varicella Attenuated Live Vaccine Revenue 2020-2025 ($ millions)
Figure 29. APAC Varicella Attenuated Live Vaccine Sales 2020-2025 (K Doses)
Figure 30. APAC Varicella Attenuated Live Vaccine Revenue 2020-2025 ($ millions)
Figure 31. Europe Varicella Attenuated Live Vaccine Sales 2020-2025 (K Doses)
Figure 32. Europe Varicella Attenuated Live Vaccine Revenue 2020-2025 ($ millions)
Figure 33. Middle East & Africa Varicella Attenuated Live Vaccine Sales 2020-2025 (K Doses)
Figure 34. Middle East & Africa Varicella Attenuated Live Vaccine Revenue 2020-2025 ($ millions)
Figure 35. Americas Varicella Attenuated Live Vaccine Sales Market Share by Country in 2025
Figure 36. Americas Varicella Attenuated Live Vaccine Revenue Market Share by Country (2020-2025)
Figure 37. Americas Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Figure 38. Americas Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Figure 39. United States Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 40. Canada Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 41. Mexico Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 42. Brazil Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 43. APAC Varicella Attenuated Live Vaccine Sales Market Share by Region in 2025
Figure 44. APAC Varicella Attenuated Live Vaccine Revenue Market Share by Region (2020-2025)
Figure 45. APAC Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Figure 46. APAC Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Figure 47. China Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 48. Japan Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 49. South Korea Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 50. Southeast Asia Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 51. India Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 52. Australia Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. China Taiwan Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. Europe Varicella Attenuated Live Vaccine Sales Market Share by Country in 2025
Figure 55. Europe Varicella Attenuated Live Vaccine Revenue Market Share by Country (2020-2025)
Figure 56. Europe Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Figure 57. Europe Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Figure 58. Germany Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 59. France Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 60. UK Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 61. Italy Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 62. Russia Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. Middle East & Africa Varicella Attenuated Live Vaccine Sales Market Share by Country (2020-2025)
Figure 64. Middle East & Africa Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Figure 65. Middle East & Africa Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Figure 66. Egypt Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 67. South Africa Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 68. Israel Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 69. Turkey Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 70. GCC Countries Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Varicella Attenuated Live Vaccine in 2025
Figure 72. Manufacturing Process Analysis of Varicella Attenuated Live Vaccine
Figure 73. Industry Chain Structure of Varicella Attenuated Live Vaccine
Figure 74. Channels of Distribution
Figure 75. Global Varicella Attenuated Live Vaccine Sales Market Forecast by Region (2026-2031)
Figure 76. Global Varicella Attenuated Live Vaccine Revenue Market Share Forecast by Region (2026-2031)
Figure 77. Global Varicella Attenuated Live Vaccine Sales Market Share Forecast by Type (2026-2031)
Figure 78. Global Varicella Attenuated Live Vaccine Revenue Market Share Forecast by Type (2026-2031)
Figure 79. Global Varicella Attenuated Live Vaccine Sales Market Share Forecast by Application (2026-2031)
Figure 80. Global Varicella Attenuated Live Vaccine Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Varicella Attenuated Live Vaccine
Figure 2. Varicella Attenuated Live Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Varicella Attenuated Live Vaccine Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Varicella Attenuated Live Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Varicella Attenuated Live Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Varicella Attenuated Live Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Varicella Attenuated Live Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Monovalent Vaccine
Figure 12. Product Picture of Combination Vaccine
Figure 13. Global Varicella Attenuated Live Vaccine Sales Market Share by Type in 2025
Figure 14. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2020-2025)
Figure 15. Varicella Attenuated Live Vaccine Consumed in Kids Injection
Figure 16. Global Varicella Attenuated Live Vaccine Market: Kids Injection (2020-2025) & (K Doses)
Figure 17. Varicella Attenuated Live Vaccine Consumed in Adults Injection
Figure 18. Global Varicella Attenuated Live Vaccine Market: Adults Injection (2020-2025) & (K Doses)
Figure 19. Global Varicella Attenuated Live Vaccine Sale Market Share by Application (2024)
Figure 20. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application in 2025
Figure 21. Varicella Attenuated Live Vaccine Sales by Company in 2025 (K Doses)
Figure 22. Global Varicella Attenuated Live Vaccine Sales Market Share by Company in 2025
Figure 23. Varicella Attenuated Live Vaccine Revenue by Company in 2025 ($ millions)
Figure 24. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company in 2025
Figure 25. Global Varicella Attenuated Live Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 26. Global Varicella Attenuated Live Vaccine Revenue Market Share by Geographic Region in 2025
Figure 27. Americas Varicella Attenuated Live Vaccine Sales 2020-2025 (K Doses)
Figure 28. Americas Varicella Attenuated Live Vaccine Revenue 2020-2025 ($ millions)
Figure 29. APAC Varicella Attenuated Live Vaccine Sales 2020-2025 (K Doses)
Figure 30. APAC Varicella Attenuated Live Vaccine Revenue 2020-2025 ($ millions)
Figure 31. Europe Varicella Attenuated Live Vaccine Sales 2020-2025 (K Doses)
Figure 32. Europe Varicella Attenuated Live Vaccine Revenue 2020-2025 ($ millions)
Figure 33. Middle East & Africa Varicella Attenuated Live Vaccine Sales 2020-2025 (K Doses)
Figure 34. Middle East & Africa Varicella Attenuated Live Vaccine Revenue 2020-2025 ($ millions)
Figure 35. Americas Varicella Attenuated Live Vaccine Sales Market Share by Country in 2025
Figure 36. Americas Varicella Attenuated Live Vaccine Revenue Market Share by Country (2020-2025)
Figure 37. Americas Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Figure 38. Americas Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Figure 39. United States Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 40. Canada Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 41. Mexico Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 42. Brazil Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 43. APAC Varicella Attenuated Live Vaccine Sales Market Share by Region in 2025
Figure 44. APAC Varicella Attenuated Live Vaccine Revenue Market Share by Region (2020-2025)
Figure 45. APAC Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Figure 46. APAC Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Figure 47. China Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 48. Japan Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 49. South Korea Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 50. Southeast Asia Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 51. India Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 52. Australia Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. China Taiwan Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. Europe Varicella Attenuated Live Vaccine Sales Market Share by Country in 2025
Figure 55. Europe Varicella Attenuated Live Vaccine Revenue Market Share by Country (2020-2025)
Figure 56. Europe Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Figure 57. Europe Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Figure 58. Germany Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 59. France Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 60. UK Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 61. Italy Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 62. Russia Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. Middle East & Africa Varicella Attenuated Live Vaccine Sales Market Share by Country (2020-2025)
Figure 64. Middle East & Africa Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2025)
Figure 65. Middle East & Africa Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2025)
Figure 66. Egypt Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 67. South Africa Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 68. Israel Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 69. Turkey Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 70. GCC Countries Varicella Attenuated Live Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Varicella Attenuated Live Vaccine in 2025
Figure 72. Manufacturing Process Analysis of Varicella Attenuated Live Vaccine
Figure 73. Industry Chain Structure of Varicella Attenuated Live Vaccine
Figure 74. Channels of Distribution
Figure 75. Global Varicella Attenuated Live Vaccine Sales Market Forecast by Region (2026-2031)
Figure 76. Global Varicella Attenuated Live Vaccine Revenue Market Share Forecast by Region (2026-2031)
Figure 77. Global Varicella Attenuated Live Vaccine Sales Market Share Forecast by Type (2026-2031)
Figure 78. Global Varicella Attenuated Live Vaccine Revenue Market Share Forecast by Type (2026-2031)
Figure 79. Global Varicella Attenuated Live Vaccine Sales Market Share Forecast by Application (2026-2031)
Figure 80. Global Varicella Attenuated Live Vaccine Revenue Market Share Forecast by Application (2026-2031)
